Zhang Ting, Zhang Lei, Xu Yiyao, Lu Xin, Zhao Haitao, Yang Huayu, Sang Xinting
Department of Liver Surgery, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Peking Union Medical College Hospital Beijing, China.
Am J Cancer Res. 2020 Jun 1;10(6):1658-1667. eCollection 2020.
Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality rate worldwide. Due to aggressive and invasive characteristics of HCC, poor prognosis is often displayed at advanced stages while therapeutic options are limited. Liver resection is still an essential curative-intent treatment in HCC management, while locoregional and systematic therapies made promising advances that may improve the proportion and outcomes of patients who are surgical candidates. In this review, we discussed status of currently available neoadjuvant treatments aimed at improving resectability and reducing recurrence rates. More than ever, in order to implement this therapeutic concepts and exploit the full potential of neoadjuvant treatment strategies, it is of utmost importance to use more high-level evidence to guide treatment decision making. Unfortunately, the use of preoperative treatments is not sponsored by tough evidence and consensus guidelines are absent.
肝细胞癌（HCC）是全球最常见且死亡率很高的癌症之一。由于HCC具有侵袭性和转移性特征，晚期患者的预后通常较差，而治疗选择有限。肝切除术仍是HCC治疗中至关重要的根治性治疗方法，同时局部和全身治疗取得了有前景的进展，可能会提高适合手术患者的比例和改善其治疗效果。在本综述中，我们讨论了旨在提高可切除性和降低复发率的现有新辅助治疗的现状。比以往任何时候都更重要的是，为了实施这一治疗理念并充分发挥新辅助治疗策略的潜力，使用更多高级别证据来指导治疗决策至关重要。不幸的是，术前治疗的应用缺乏有力证据支持，且尚无共识性指南。
